Medtronic Announces TYRX Antibacterial Envelope Trial Results
Medtronic’ TYRX antibacterial envelope cuts down on major cardiac device site infections by 80 percent for up to 12 months following implantation, the Irish devicemaker announced Friday at the Heart Rhythm 2015 conference in Boston, Mass.
Cardiac implantable electronic device infections are increasing and have been linked with serious illness, mortality and high costs, the company says. During a series of multicenter clinical trials, Medtronic tested the envelope for infection-reducing CIED efficacy.
The device has a mesh layer meant to contain and stabilize an implantable cardiac device. It releases two antimicrobial agents over a minimum of seven days to reduce infection. Nine weeks after surgery, the envelope is fully absorbed by the body.
The product is available in the U.S. and EU. — Jason Scott